Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ImmunityBio Inc. is conducting a clinical trial titled ‘QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer.’ The study aims to evaluate the efficacy of combining BCG with N-803 in treating patients with high-grade non-muscle invasive bladder cancer unresponsive to BCG alone. This trial is significant as it explores potential new treatment avenues for a challenging cancer type.
The intervention being tested involves two drugs: N-803 and BCG. These are administered intravesically, meaning directly into the bladder, to enhance the immune response against cancer cells. The combination aims to improve outcomes for patients who have not responded to BCG treatment alone.
This is an interventional, open-label, single-arm study, meaning all participants receive the same treatment without a placebo group. The primary purpose is treatment-focused, and there is no masking, allowing both researchers and participants to know the treatment being administered.
The study began on June 2, 2017, and is currently active but not recruiting new participants. The last update was submitted on July 7, 2025. These dates are crucial as they provide a timeline for the study’s progress and expected completion.
The ongoing study could impact ImmunityBio’s stock performance positively if results show a significant improvement in treatment outcomes. Investors may view this as a promising development in the cancer treatment landscape, potentially influencing market dynamics. Competitors in the oncology space will be closely watching these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.